• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Bayes syndrome: Improving risk stratification in chronic heart failure?
The progressive ageing of population is leading to a significant increase of the incidence of heart failure (HF), one of the epidemics of the 21th Century. In addition, atrial fibrillation (AF) is the most common arrhythmia in elderly patients, and is associated with a higher incidence of stroke and mortality. A significant association between HF and AF has been consistently described, and its combination increases morbidity and mortality.
Source: International Journal of Cardiology - June 13, 2018 Category: Cardiology Authors: Albert Ariza-Sol é, Carme Guerrero, Francesc Formiga Tags: Editorial Source Type: research

Heart failure and the development of atrial fibrillation in Hispanics, African Americans and non-Hispanic Whites
Atrial fibrillation (AF) is the most common cardiac arrhythmia [1], whose prevalence is increasing [1,2]. It represents a major public health problem and is closely related to stroke, mortality, decreased quality of life and a high health-care cost burden [3]. Heart failure (HF) is a growing epidemic and likely to impact 9 million US adults by 2030 [16]. AF and HF are closely linked [5], sharing similar risk factors with neurohormonal, cellular, extracellular and electrophysiologic changes of one predisposing the other [6 –8].
Source: International Journal of Cardiology - May 22, 2018 Category: Cardiology Authors: Eric Shulman, Tina Shah, Alon Y. Mazori, Jay J. Chudow, Faraj Kargoli, Dmitriy Nevelev, Jorge Romero, Luigi Di Biase, John Fisher, Jay Gross, Kevin J. Ferrick, Andrew Krumerman Source Type: research

Laparoscopic Sleeve Gastrectomy in Patients with Heart Failure and Left Ventricular Assist Devices as a Bridge to Transplant
Obesity is an epidemic that is progressive, costly, and closely associated with cardiac disease and death. Obesity causes structural and functional changes in the heart due to increases in metabolic demand, total blood volume, and stroke volume, all of which cause left ventricular dilation, cardiac muscle hypertrophy, and atrial enlargement [1,2]. Heart failure is a deadly condition, affecting up to 5.8 million people in the United States with associated health care costs exceeding 30 billion dollars per year [3,4].
Source: Surgery for Obesity and Related Diseases - April 18, 2018 Category: Surgery Authors: Russell B Hawkins, Kristina Go, Steven L Raymond, Alexander Ayzengart, Jeffrey Friedman Source Type: research

Rate or Rhythm Control of Atrial Fibrillation - Pearls for the Internist.
Abstract Atrial fibrillation is an epidemic in Asia that is increasingly prevalent. Apart from stroke risk stratification and management of anticoagulation, physicians managing this group of patients also need to determine an optimal strategy in terms of rate or rhythm control. With new techniques of catheter ablation to maintain patients in sinus rhythm, patients with atrial fibrillation now have more options for treatment, on top of pharmacological methods. This paper aims to review the current evidence for rate and rhythm control in both general patients and subgroups of interest commonly encountered in clinica...
Source: Annals of the Academy of Medicine, Singapore - November 1, 2017 Category: General Medicine Authors: Huang W, Keng FY, Ching CK Tags: Ann Acad Med Singapore Source Type: research

Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times.
Authors: Batul SA, Gopinathannair R Abstract Atrial fibrillation (AF) and heart failure (HF) are growing cardiovascular disease epidemics worldwide. There has been an exponential increase in the prevalence of AF and HF correlating with an increased burden of cardiac risk factors and improved survival rates in patients with structural heart disease. AF is associated with adverse prognostic outcomes in HF and is most evident in mild-to-moderate left ventricular (LV) dysfunction where the loss of "atrial kick" translates into poorer quality of life and increased mortality. In the absence of underlying structural heart...
Source: Korean Circulation Journal - September 29, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Editorial commentary: New drugs for diabetes: Finally safety and cardiovascular efficacy
Diabetes mellitus has emerged as the epidemic of the modern age [1]. Concomitant with this, we have witnessed a rise in the complications of this condition, with diabetes now the number one cause of end stage renal failure in developed nations and ~75% of deaths in the overall diabetic population being related to cardiovascular disease, primarily stroke, myocardial infarction and heart failure [2].
Source: Trends in Cardiovascular Medicine - February 24, 2017 Category: Cardiology Authors: Kim A. Connelly Source Type: research

New drugs for Diabetes: Finally safety and cardiovascular efficacy
Diabetes mellitus has emerged as the epidemic of the modern age [1]. Concomitant with this, we have witnessed a rise in the complications of this condition, with diabetes now the number one cause of end stage renal failure in developed nations and ~75% of deaths in the overall diabetic population being related to cardiovascular disease, primarily stroke, myocardial infarction and heart failure [2].
Source: Trends in Cardiovascular Medicine - February 23, 2017 Category: Cardiology Authors: Kim A. Connelly Source Type: research

Nanocarriers as treatment modalities for hypertension.
Authors: Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J Abstract Hypertension, a worldwide epidemic at present, is not a disease in itself rather it is an important risk factor for serious cardiovascular disorders including myocardial infarction, stroke, heart failure, and peripheral artery disease. Though numerous drugs acting via different mechanism of action are available in the market as conventional formulations for the treatment of hypertension but they face substantial challenges regarding their bioavailability, dosing and associated adverse effects which greatly limit their therapeutic efficacies. Vari...
Source: Drug Delivery - February 8, 2017 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Why should we screen for atrial fibrillation?
Atrial fibrillation (AF) constitutes an increasing challenge to the medical community and healthcare providers. With a prevalence of almost 3% in the adult Swedish population1 and a forecasted twofold or threefold increase by 2050 in the USA, we are facing a diagnosis with epidemic proportions. Apart from increased mortality, AF also increases the risk of heart failure, hospitalisations and ischaemic stroke.2 Of these complications, ischaemic stroke gives a particularly heavy burden on patients, their family and society. Ischaemic stroke is the most common reason for permanent neurological disability in the adult Western p...
Source: Heart - December 8, 2016 Category: Cardiology Authors: Svennberg, E., Engdahl, J. Tags: Press releases, Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

Alcoholic cardiomyopathy : The result of dosage and individual predisposition.
Authors: Maisch B Abstract The individual amount of alcohol consumed acutely or chronically decides on harm or benefit to a person's health. Available data suggest that one to two drinks in men and one drink in women will benefit the cardiovascular system over time, one drink being 17.6 ml 100 % alcohol. Moderate drinking can reduce the incidence and mortality of coronary artery disease, heart failure, diabetes, ischemic and hemorrhagic stroke. More than this amount can lead to alcoholic cardiomyopathy, which is defined as alcohol toxicity to the heart muscle itself by ethanol and its metabolites. Historical exa...
Source: Herz - September 3, 2016 Category: Cardiology Tags: Herz Source Type: research

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it�...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Endocannabinoids and cardiovascular prevention: real progress?
Authors: Nodari S, Manerba A, Metra M, Dei Cas L Abstract The prevalence of obesity continues to increase and represents one of the principal causes of cardiovascular morbidity and mortality. After the discovery of a specific receptor of the psychoactive principle of marijuana, the cannabinoid receptors and their endogenous ligands, several studies have demonstrated the role of this system in the control of food intake and energy balance and its overactivity in obesity. Recent studies with the CB1 receptor antagonist rimonabant have demonstrated favorable effects such as a reduction in body weight and waist circumf...
Source: Heart International - November 28, 2015 Category: Cardiology Tags: Heart Int Source Type: research

New journal JAMA Cardiology to debut in 2016
As cardiovascular disease remains the No. 1 cause of death and disability worldwide, a new medical journal will premiere early next year to serve the global cardiology community. JAMA Cardiology—to be led by an internationally renowned cardiologist—will premiere as the 12th journal in the JAMA Network, which includes JAMA and 10 other specialty journals. “The burden of hypertension, ischemic heart disease, heart failure, stroke, valvular heart disease and atrial fibrillation is reaching epidemic proportions worldwide,” writes Howard Bauchner, MD, editor in chief of The JAMA Network, and colleagues in a JAMA edito...
Source: AMA Wire - October 12, 2015 Category: Journals (General) Authors: Amy Farouk Source Type: news

JAMA Cardiology—A New JAMA Network Journal
Cardiovascular disease remains the leading cause of death and disability worldwide, in developed and developing countries. Despite the success in the last decade in reducing heart disease–related mortality in many countries, with aging of the population and persistent cardiovascular risk factors, the burden of hypertension, ischemic heart disease, heart failure, stroke, valvular heart disease, and atrial fibrillation is reaching epidemic proportions worldwide.
Source: JAMA - Journal of the American Medical Association - October 12, 2015 Category: Journals (General) Source Type: research

Pages: 1  2  3  4